OncoSenX, Inc., a Seattle, WA-based late preclinical-stage company developing therapeutics to kill cancer cells based on their genetics, raised $3m in pre-seed funding.
The backers were not disclosed.
The company intends to use the funds to accelerate the preclinical research necessary to begin phase 1 clinical development.
Led by Matthew Scholz, chief executive officer, and John Lewis, Ph.D., chief science officer, OncoSenX is developing a highly selective tumor-killing platform with two main components:
– a proprietary lipid nanoparticle (LNP) for cellular delivery and
– a highly selective DNA payload.
The LNP is designed to deliver its non-integrating DNA payload to solid tumors, while an engineered promoter drives expression of a potent, inducible death protein only in the target cell population. The goal is to precisely target cell populations based on their genetic activity without harming nearby cells. The platform can be effectively programmed to implement logic gates (IF/OR/AND) to provide selectivity to any target cell based on its genetics.
The company is currently preparing for its regulatory interactions and will then perform pivotal toxicology studies in anticipation of filing to begin human trials.